Navigation Links
Treatment for S. aureus skin infection works in mouse model
Date:8/31/2010

Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States. By neutralizing a key toxin associated with the bacteria, they found they could greatly reduce the damaging effects of the infection on skin and soft tissue. Community strains of S. aureus cause infection in otherwise healthy people and are considered extremely virulent, as opposed to hospital strains that infect people who already are weakened by illness or surgery.

While much recent attention has been focused on deaths caused by S. aureus infection in the bloodstreamand those caused by methicillin-resistant S. aureus in particularthe Centers for Disease Control and Prevention estimates that in 2005, physicians treated 14 million non-lethal S. aureus skin and softtissue cases in the United States.

In their study, now online in The Journal of Infectious Diseases, scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) examined the effects of the bacterial toxin alpha-hemolysin, or Hla, on S. aureus skin infections in laboratory mice. In all aspects of the study where the Hla toxin was either removed from S. aureus bacteria or neutralized through immunization, skin abscesses were significantly smaller, mice recovered faster and there was little or no skin destruction.

When S. aureus secretes Hla during infection in humans, the toxin pokes holes in a variety of different host cells, killing them. Scientists who have studied Hla for years have mainly focused on neutralizing the toxin in cases of pneumonia-related S. aureus infection. Until now, no one had tested how the absence of Hla would affect the severity of USA300 skin infections and whether immunization against the toxin could neutralize Hla and its contribution to the severity of skin disease.

"For cases of skin and soft-tissue infection caused by Staph aureus, this study highlights the potential for antitoxin treatment to become an effective alternative to traditional antibiotics, which we know have limitations because of drug resistance," says NIAID Director Anthony S. Fauci, M.D. Antitoxins prevent harm caused by a specific part of a pathogensuch as Hla in S. aureusrather than trying to kill the entire pathogen, as antibiotics do.

The study, led by Frank DeLeo, Ph.D., of NIAID's Rocky Mountain Laboratories in Hamilton, Mont., documented physical differences in mice infected with different strains of S. aureus, including USA300 with or without Hla. The second portion of the study tested what is known as active and passive immunity, with mice being immunized with a non-lethal version of the toxin or injected with Hla-specific antibodies, respectively. Both types of immunization protected mice from skin lesions that typically destroy skin and surrounding tissue.

The group noted that multiple S. aureus molecules must contribute to skin infection because simply removing or neutralizing Hla did not completely prevent the formation of skin abscesses, although the abscesses were smaller in size.

Study collaborators from the University of Chicago, Olaf Schneewind, M.D., Ph.D., and Juliane Bubeck Wardenburg, M.D., Ph.D.,contributed the Hla treatment concept, which they developed through their recent work on S. aureus pneumonia. Dr. DeLeo's group adapted that work to their mouse model of skin infection, which is a good indicator of how abscess size and skin destruction could affect humans, according to the study investigators.

"This toxin is probably one of the most promising targets we currently have in our efforts to develop therapeutics that protect against severe Staph aureus skin infections," says Dr. DeLeo. His group is continuing its collaboration with Drs. Schneewind and Bubeck Wardenburg on the project.


'/>"/>

Contact: Ken Pekoc
kpekoc@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert  

Related medicine news :

1. Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders
2. Drug trial results refine treatment during angioplasty operations
3. Research demonstrates benefits of medical cannabis as a treatment for chronic pain
4. Some Fake ADHD to Get Meds, Special Treatment
5. Experimental treatments for cocaine addiction may prevent relapse
6. Society of Interventional Radiology supports research for new MS treatments
7. Mayo researchers develop new laboratory cell lines to study treatment for ATC
8. A promising target for developing treatments against Parkinsons disease
9. Cost of prostate cancer care varies with initial treatment choice
10. Significant advance announced in treatment of cervical cancer
11. With muscle-building treatment, mice live longer even as tumors grow
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treatment for S. aureus skin infection works in mouse model
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: